Genelux Co. (NASDAQ:GNLX) Shares Sold by Millennium Management LLC

Millennium Management LLC reduced its position in Genelux Co. (NASDAQ:GNLX - Free Report) by 58.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 150,510 shares of the company's stock after selling 214,419 shares during the period. Millennium Management LLC owned 0.44% of Genelux worth $355,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Apollon Wealth Management LLC boosted its stake in Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after purchasing an additional 2,857 shares during the period. LifeSteps Financial Inc. boosted its stake in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after buying an additional 8,715 shares during the period. Virtu Financial LLC purchased a new position in shares of Genelux during the fourth quarter worth about $25,000. Raymond James Financial Inc. purchased a new position in shares of Genelux in the 4th quarter valued at approximately $41,000. Finally, D.A. Davidson & CO. purchased a new position in shares of Genelux in the 4th quarter valued at approximately $51,000. Institutional investors and hedge funds own 37.33% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GNLX. Benchmark decreased their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Genelux in a research note on Monday, March 31st. Finally, Wall Street Zen lowered shares of Genelux from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.75.

Genelux Price Performance

Shares of NASDAQ GNLX traded down $0.05 during trading on Thursday, hitting $2.60. 7,035 shares of the company were exchanged, compared to its average volume of 187,696. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $5.89. The company has a market cap of $98.11 million, a price-to-earnings ratio of -2.74 and a beta of -0.49. The firm's fifty day moving average price is $2.56 and its 200 day moving average price is $3.06.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.03. On average, research analysts forecast that Genelux Co. will post -0.88 earnings per share for the current year.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.